Search Results - "Herrmann, Ken"

Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy.

Authors: Voltin, Conrad-Amadeus Flossdorf, Sarah Kurch, Lars et al.

Source: Journal of Nuclear Medicine. Jun2026, Vol. 67 Issue 6, p871-877. 7p.

Early timepoint ^99mTc-DPD whole body scintigraphy and quantitative SPECT/CT imaging for diagnosis of cardiac ATTR amyloidosis.

Authors: Settelmeier, Stephan Kessler, Lukas Hammersen, Noah et al.

Source: EJNMMI Research. 6/12/2026, Vol. 16 Issue 1, p1-11. 11p.

Diagnostic Potential of Apparent Diffusion Coefficient-Based Lymph Node Classification in Breast Cancer Patients Undergoing [ 18 F]FDG-PET/MRI.

Authors: Peters, Helena A. Scheuer, Marie Weiss, Daniel et al.

Source: Diagnostics (2075-4418). Jun2026, Vol. 16 Issue 11, p1712. 17p.

European Association of Nuclear Medicine (EANM) response to the proposed ASTRO's framework for radiopharmaceutical therapy curriculum development for trainees.

Authors: Dierckx, Rudi Herrmann, Ken Hustinx, Roland et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Dec2022, Vol. 50 Issue 1, p1-3. 3p.

The Pelvic Rosetta Classification Project: An Interdisciplinary Proposal for a Lymph Node Map of the Pelvis in Prostate Cancer.

Authors: Ortner, Gernot Hoderlein, Xenia Barbato, Francesco et al.

Source: Journal of Nuclear Medicine. Jan2026, Vol. 67 Issue 1, p154-159. 6p.

⁹⁰Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort Analysis.

Authors: Lanzafame, Helena Mavroeidi, Ilektra A. Pabst, Kim M. et al.

Source: Journal of Nuclear Medicine. May2026, Vol. 67 Issue 5, p744-750. 7p.

Reliability and Practicability of FAP-RADS Version 1.0 for Structured Reporting of FAPI Imaging in Pulmonary and Urothelial Carcinoma.

Authors: Novruzov, Emil Mamlins, Eduards Widjaja, Liam et al.

Source: Journal of Nuclear Medicine. May2026, Vol. 67 Issue 5, p687-692. 6p.

Mapping the knowledge landscape of the PET/MR domain: a multidimensional bibliometric analysis.

Authors: Hu, Xiaofei Peng, Jianding Huang, Min et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Apr2025, Vol. 52 Issue 5, p1805-1821. 17p.

Radiation Dose-Dependent and -Independent Pulmonary Infiltrates in Patients with High-Grade Pneumonitis After Radiochemotherapy and Durvalumab Consolidation for Stage III NSCLC.

Authors: Herz, Andreas Khouya, Aymane Guberina, Maja et al.

Source: Diagnostics (2075-4418). Mar2026, Vol. 16 Issue 6, p827. 21p.

Comparison between [⁶⁸Ga]Ga-FAPI-46 and [¹⁸F]FDG PET/CT uptake in luminal-like vs. HER2-positive breast cancer.

Authors: Küper, Alina Toni Vaz, Sofia Carrilho Pabst, Kim Magaly et al.

Source: EJNMMI Research. 3/13/2026, Vol. 16 Issue 1, p1-12. 12p.

Ensuring enantiomeric consistency in FAPI radiopharmaceuticals: comparative analysis of (S)- and (S/R)-FAPI-46/-74 confirms pharmacological equivalence.

Authors: Staniszewska, Magdalena Hübner, Ralph Locatelli, Camilla et al.

Source: EJNMMI Radiopharmacy & Chemistry. 2/28/2026, Vol. 11 Issue 1, p1-13. 13p.

EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy.

Authors: Konijnenberg, Mark Herrmann, Ken Kobe, Carsten et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. 2021, Vol. 48 Issue 1, p67-72. 6p. 1 Chart.

Precision Medicine Is Critical for the Future of Oncology: Johannes Czernin and Ken Herrmann Talk with Chris Behrenbruch on Theranostics, Imaging, and the Urgency to Innovate.

Authors: Behrenbruch, Christian Herrmann, Ken Czernin, Johannes

Source: Journal of Nuclear Medicine. Sep2025, Vol. 66 Issue 9, p1319-1322. 4p.

PET imaging utilization and trends in Germany: a comprehensive survey.

Authors: Holzgreve, Adrien Hellwig, Dirk Barthel, Henryk et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Oct2025, Vol. 52 Issue 12, p4390-4398. 9p.

Efficacy of [¹⁸F]PSMA-1007 PET/CT in Primary Staging of Prostate Carcinoma: A Systematic Review and Metaanalysis.

Authors: Rahbar, Kambiz Giesel, Frederik L. Herrmann, Ken et al.

Source: Journal of Nuclear Medicine. Jan2026, Vol. 67 Issue 1, p85-91. 7p.

Clinical Impact of Changes in Tumor Uptake and Volume on PSMA PET/CT During [¹⁷⁷Lu]Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer.

Authors: Djaileb, Loïc Farolfi, Andrea Rauscher, Isabel et al.

Source: Journal of Nuclear Medicine. Jan2026, Vol. 67 Issue 1, p92-95. 4p.

Prognostic Value of Fibroblast Activation Protein–Directed PET Imaging in Pleural Mesothelioma.

Authors: Kessler, Lukas Schwaning, Felix Metzenmacher, Martin et al.

Source: Journal of Nuclear Medicine. Mar2026, Vol. 67 Issue 3, p383-390. 8p.

⁹⁰Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous Tumors.

Authors: Lanzafame, Helena Heilig, Christoph E. Wardelmann, Eva et al.

Source: Journal of Nuclear Medicine. Sep2025, Vol. 66 Issue 9, p1378-1384. 7p.

Theranostics in Perspective: White Paper.

Authors: Stokkel, Marcel P.M. Gotthardt, Martin Herrmann, Ken et al.

Source: Journal of Nuclear Medicine. Jul2026, Vol. 67 Issue 7, p1007-1011. 5p.

Correction to: European Association of Nuclear Medicine (EANM) response to the proposed ASTRO's framework for radiopharmaceutical therapy curriculum development for trainees.

Authors: Dierckx, Rudi Herrmann, Ken Hustinx, Roland et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Jan2023, Vol. 50 Issue 2, p630-630. 1p.